Skip to main content
OpenTrials
Completed

NCT Number: NCT00975455

Hematuria Evaluation Trial for Subjects With Microscopic or Gross Hematuria to Determine the Absence or Presence of Bladder Cancer

The purpose of the study is to evaluate subjects with gross or microscopic hematuria undergoing scheduled cystoscopy to determine the absence or presence of bladder cancer.

Completed

Looking for future studies?

Notify Me

Key information

Age range

45 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Atlantic Urological Associates, Daytona Beach, Florida, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • For those subjects for whom there is no family history of bladder cancer or less than a 20 pack year history of cigarette smoking, subject must be 50 or older.
  • Subject's age can be lowered to 45 or older if there is a family history of bladder cancer and/or a 20 or greater pack history of cigarette smoking.
  • Subject must have an intact bladder
  • Subject must be scheduled to have a cystoscopy to screen for transitional call bladder cancer due to the finding of hematuria.
  • Subject must be able to provide a minimum of 25 mL of urine for study purposes.
  • Urine samples must be available prior to cystoscopy, bladder biopsy, and TUR.
  • Subjects must be willing to sign an Institutional Review Board approved written informed consent prior to any study related procedures being performed.

Exclusion criteria

  • Subject had a history or current diagnosis of any basal or squamous cell cancer.
  • Subject had a known diagnosis of any autoimmune disease.
  • Subject had known diagnosis of HIV, HCV or HBV
  • Subject had disclosed voluntarily history of or current infection with TB or other systemic disease.
  • Subject is currently pregnant or lactating.
  • Subject had surgery within 30 days prior to enrollment
  • Subject has known allergy to benzalkonium chloride.
  • Subject participated in an investigational drug or device trial within 30 days prior to enrollment.

Treatment and study plan

Primary outcomes

  1. To establish the performance characteristics of the Predictive Biosciences Assay relative to the cystoscopy results for subjects undergoing evaluation for the referral diagnosis of gross or microscopic hematuria

    Time frame: Initial Visit only

Secondary outcomes

  1. To establish the performance characteristics of the PB assay relative to urine cytology results for subjects undergoing evaluation for the referral diagnosis of gross or microscopic hematuria.

    Time frame: Initial Visit

Sponsors and collaborators

Lead sponsor

Predictive Biosciences

Industry

Registry information

Official study title

Phase 3 Study of Hematuria Evaluation

Important dates

Study start
2009
Primary completion
2010
Study completion
2011
First posted
Sep 11, 2009
Registry last updated
Jun 8, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.